Fidia S.p.A. (BIT: FDA)
Italy
· Delayed Price · Currency is EUR
0.0408
-0.0030 (-6.85%)
Dec 20, 2024, 5:35 PM CET
Fidia Revenue
Fidia had revenue of 9.42M EUR in the half year ending June 30, 2024, a decrease of -0.16%. This brings the company's revenue in the last twelve months to 29.17M, up 20.45% year-over-year. In the year 2023, Fidia had annual revenue of 28.74M with 16.52% growth.
Revenue (ttm)
29.17M
Revenue Growth
+20.45%
P/S Ratio
0.02
Revenue / Employee
170.57K
Employees
193
Market Cap
1.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
Dec 31, 2019 | 46.20M | -12.65M | -21.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Poste Italiane S.p.A. | 13.25B |
Webuild S.p.A. | 10.01B |
Maire S.p.A. | 5.28B |
Iveco Group N.V. | 15.75B |
Fincantieri S.p.A. | 7.46B |
Danieli & C. Officine Meccaniche S.p.A. | 4.32B |
Rai Way S.p.A. | 274.27M |
Piovan S.p.A. | 560.64M |
Fidia News
- 13 hours ago - Financial Crime Weekly: Becton, Dickinson And Co. Pays $175 Million Penalty, Express Fails To Disclose CEO's Full Compensation - Benzinga
- 14 hours ago - FDA approves weight-loss drug to treat sleep apnea - The Hill
- 14 hours ago - Novo Nordisk bleeding prevention injection for hemophilia granted FDA nod - Seeking Alpha
- 20 hours ago - Popular Dog Arthritis Medication May Have Severe Side Effects, FDA Says - NDTV
- 1 day ago - FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors - Benzinga
- 1 day ago - Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? - Investor's Business Daily
- 1 day ago - Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments - GuruFocus
- 1 day ago - FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha